{"filing":{"accession_number":"0001193125-26-232524","cik":"0001055726","ticker":"INO","company_name":"INOVIO PHARMACEUTICALS, INC.","form":"8-K","filing_date":"2026-05-20","report_date":null,"primary_document":"d138309d8k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1055726/000119312526232524/d138309d8k.htm"},"events":[{"id":9787,"run_id":8581,"accession_number":"0001193125-26-232524","anchor_item_number":"5.07","event_type":"shareholder_vote_results","event_domain":"governance","is_material":true,"confidence":0.98,"summary":"Inovio Pharmaceuticals held its 2026 Annual Meeting of Stockholders on May 20, 2026, with shareholders voting on four proposals: election of eight directors, ratification of Ernst \u0026 Young LLP as independent auditor, advisory approval of named executive officer compensation, and approval of an amended 2023 Omnibus Incentive Plan. All proposals passed with substantial majorities.","company_name":"INOVIO PHARMACEUTICALS, INC.","ticker":"INO","filing_date":"2026-05-20","form":"8-K","submitted_at":null,"items":[{"id":586,"accession_number":"0001193125-26-232524","item_number":"5.07","item_title":null,"event_type":"shareholder_vote_results","event_domain":"governance","is_material":true,"confidence":0.98,"reasoning":"This is a clear disclosure of shareholder vote results from the Company's 2026 Annual Meeting of Stockholders held on May 20, 2026, filed under Item 5.07. The filing reports voting outcomes for four proposals: election of eight directors, ratification of Ernst \u0026 Young LLP as independent auditor, advisory approval of NEO compensation, and approval of an amended 2023 Omnibus Incentive Plan. All proposals passed with substantial majorities. This is material as it reflects stockholder governance decisions and approval of key corporate matters.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-05-21T02:46:28.425345+00:00","company_name":"","ticker":null,"filing_date":""}]},{"id":9788,"run_id":8581,"accession_number":"0001193125-26-232524","anchor_item_number":"5.03","event_type":"other_material","event_domain":"catchall","is_material":false,"confidence":0.85,"summary":"The Company amended its bylaws to enhance corporate governance practices, including clarification of the Chairman's role, establishment of a Lead Independent Director position, and updates to the order of presiding officers. The introduction of a Lead Independent Director requirement when the CEO serves as Chairman represents a meaningful governance enhancement, though this is primarily a procedural administrative change.","company_name":"INOVIO PHARMACEUTICALS, INC.","ticker":"INO","filing_date":"2026-05-20","form":"8-K","submitted_at":null,"items":[{"id":585,"accession_number":"0001193125-26-232524","item_number":"5.03","item_title":null,"event_type":"other_material","event_domain":"catchall","is_material":false,"confidence":0.85,"reasoning":"This disclosure concerns amendments to the Company's bylaws to enhance corporate governance practices, including clarification of the Chairman's role, establishment of a Lead Independent Director position, and updates to the order of presiding officers. While bylaw amendments are routine administrative matters, the introduction of a Lead Independent Director requirement when the CEO serves as Chairman represents a meaningful governance enhancement that could affect investor assessment of board independence and oversight structures. However, this is primarily a procedural/administrative change rather than a material event affecting the registrant's financial condition or operations.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-05-21T02:46:28.425345+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":585,"accession_number":"0001193125-26-232524","item_number":"5.03","item_title":null,"event_type":"other_material","event_domain":"catchall","is_material":false,"confidence":0.85,"reasoning":"This disclosure concerns amendments to the Company's bylaws to enhance corporate governance practices, including clarification of the Chairman's role, establishment of a Lead Independent Director position, and updates to the order of presiding officers. While bylaw amendments are routine administrative matters, the introduction of a Lead Independent Director requirement when the CEO serves as Chairman represents a meaningful governance enhancement that could affect investor assessment of board independence and oversight structures. However, this is primarily a procedural/administrative change rather than a material event affecting the registrant's financial condition or operations.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-05-21T02:46:28.425345+00:00","company_name":"INOVIO PHARMACEUTICALS, INC.","ticker":"INO","filing_date":"2026-05-20"},{"id":586,"accession_number":"0001193125-26-232524","item_number":"5.07","item_title":null,"event_type":"shareholder_vote_results","event_domain":"governance","is_material":true,"confidence":0.98,"reasoning":"This is a clear disclosure of shareholder vote results from the Company's 2026 Annual Meeting of Stockholders held on May 20, 2026, filed under Item 5.07. The filing reports voting outcomes for four proposals: election of eight directors, ratification of Ernst \u0026 Young LLP as independent auditor, advisory approval of NEO compensation, and approval of an amended 2023 Omnibus Incentive Plan. All proposals passed with substantial majorities. This is material as it reflects stockholder governance decisions and approval of key corporate matters.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-05-21T02:46:28.425345+00:00","company_name":"INOVIO PHARMACEUTICALS, INC.","ticker":"INO","filing_date":"2026-05-20"}]}